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Follicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up
prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by
the International Follicular Lymphoma Prognostic Factor project was established and a new prognostic study was launched (FLIPI2)
using progression-free survival (PFS) as main endpoint and integrating all the modern parameters prospectively collected. Low-
grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent
clinical course. Each entity is characterized by unique clinicobiologic features. Some studies have been focused on prognostic
factors in single lymphoma subtypes, with the development of specific-entity scores based on retrospective series, for instance
splenic marginal zone lymphoma (SMZL). A widely accepted prognostic tool for clinical usage for indolent non-follicular B-cell
lymphomas is largely awaited. In this paper we summarized the current evidence regarding prognostic assessment of indolent
follicular and non-follicular lymphomas.
1. Introduction
Indolent lymphomas represent more than half of malignant
lymphomas and include small lymphocytic lymphomas
(SLLs), lymphoplasmacytic lymphoma (LPL), follicular lym-
phomas (FLs), and marginal zone lymphomas (MZLs).
Although patients with low-grade lymphoma have an indo-
lent clinical course, patients’ prognosis is quite heterogenous
among different subtypes and within each of them. So far
several studies have investigated prognosis of indolent lym-
phomas and demonstrated that different demographic fea-
tures together with clinical and biological factors have a prog-
nostic impact including age, sex, stage, tumor burden, bulky
disease, bone marrow involvement, presence of systemic
symptoms, performance status, erythrocyte sedimentation
rate (ESR), serum lactate dehydrogenase (LDH) level, ane-
mia, thrombocytopenia, and β2-microglobulin level. The
combination of these parameters has allowed the identifica-
tion of prognostic scores in different types of lymphoma.
Attempts to define prognosis in low-grade indolent lym-
phomas begann in the late 70s. Then, when in 1993 the Inter-
national Prognostic Index (IPI) was defined for aggressive
lymphomas [1] it was also applied to low-grade lymphomas
leading to conflicting results [2, 3] and the need for a
prognostic index specifically designed for follicular as well as
for indolent non-follicular lymphomas clearly emerged.
Specific prognostic scores for follicular lymphoma have
been developed with the collection of large multicenter ret-
rospective series, as ILI (Italian Lymphoma Intergroup) score
[4] and the Follicular Lymphoma International Prognostic
Index (FLIPI) [5]. Recently, a new prognostic score for follic-
ular lymphomas (FLIPI2), based on prospective multicenter
web-based collection of data, was developed [6]. Also in SLL,
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LPL and MZL some attempts were performed that allowed
the development of lymphoma-specific prognostic scores.
2. Aim of This Paper
This paper describes currently available prognostic tools for
patients with indolent lymphoma including follicular lym-
phoma and non-follicular subtypes.
3. Follicular Lymphoma
FL is the most frequent low-grade lymphoma in western
countries, accounting for 25% of all cases [7]. FL is generally
considered a long-lasting indolent disorder but survival dur-
ation is quite heterogeneous and precise prognostication
especially in the monoclonal antibody era is greatly needed
[8]. Until now there is no consensus concerning the optimal
first-line treatment for FL patients: among possible options
patients may be observed without any specific treatment
until disease progression or may receive immunotherapy
(rituximab alone) or immunochemotherapy (combination
of rituximab and cytotoxic chemotherapies). Some coop-
erative groups such as the Groupe d’Etude des Lymphomes
Folliculaires (GELF) from France [9] and the British National
Lymphoma Investigation Group (BNLI) proposed criteria for
initiating treatment in FL patients.
More recently some studies have clearly shown a signif-
icant improvement in overall survival of FL patients in the
last 15 years when compared to historical controls [10, 11].
This improvement is mainly related to the introduction of
anti-CD20 monoclonal antibodies (MoAbs) in the treatment
arsenal. Due to the recent changes in the treatment standards
for patients with FL adequate and updated studies are war-
ranted to provide prognostic tools that are really useful in
daily practice.
4. Prognostic Factors in Follicular Lymphoma
Prognostic factors in FL reflect different aspects of the dis-
ease; some are directly related to the lymphoma biology such
as histological features (pattern, grading, and p.i.) or genetic
features and tumor microenvironment. Other factors are
connected with the tumor spread (stage, tumor burden, bone
marrow involvement, symptoms, etc.) or indirect laboratory
surrogates (LDH, anemia, and β2-microglobulin). Other
factors are related to disease modifications after treatment
(clinical response and minimal residual disease). Finally,
some features are not completely related to lymphoma but
are more specifically associated with the patient’s status (age,
performance status, and comorbidity) [12–14].
Regarding the prognostic impact of molecular markers,
it has been analysed the prognostic role of secondary cytoge-
netic changes [15, 16]. Another complex approach is the use
of gene expression profiling (GEP) to evaluate prognosis in
follicular lymphoma. A seminal study of GEP was performed
by the Leukemia Lymphoma Molecular Profiling Project in
nearly two thousands patients with untreated FL [17]. Two
signatures were identified: the “immune-response 1” signa-
ture, including genes encoding for T-cell markers and genes
that are preferentially expressed in macrophages, predicted a
favorable outcome and the “immune-response 2” signature,
including genes that are highly expressed in macrophages,
dendritic cells, or both, predicted an unfavorable outcome.
Other studies investigated the role of microenvironment
(follicular dendritic cells, T cells, histiocytes, and macro-
phages): results are contradictory, and this could be related
to different therapeutic approaches in analysed cohorts of
patients [18].
[18F] Fluorodeoxyglucose-positron emission tomogra-
phy (FDG-PET) is a powerful functional imaging tool in
staging and response assessment in Hodgkin lymphoma and
in diffuse large B-cell lymphoma [19, 20]. Follicular lym-
phoma is an [18F] FDG-avid disease, since more than 90%
of patients show a PET-positive disease and sensitivity of
staging PET is usually higher than 95% [21–24]. Recent data
from a large multicenter clinical trial in advanced FL patients
(PRIMA trial) showed that FDG-PET-CT status at the end
of immunochemotherapy is strongly predictive of outcome
[25].
5. Prognostic Indexes in Follicular Lymphoma
The International Prognostic Index (IPI) was originally
developed for aggressive NHLs but several groups have
tested it also in FL patients, confirming that the IPI could
discriminate FL patients into subgroups with significantly
different survival [3, 26, 27].
In 2004, the Follicular Lymphoma International Prog-
nostic Index (FLIPI) was proposed from the retrospective
analysis of more than 4,000 patients with FL treated between
1985 and 1992 [28]. After a multivariate analysis, 5 parame-
ters resulted in being predictive: age > 60 years, serum LDH
level > upper limit of normal (UNL), number of nodal areas
> 4 , and hemoglobin level < 12 g/dL. Three risk groups (low,
intermediate, and high) were distinguished (Table 1). The
efficacy of FLIPI index has been confirmed in independent
series [27, 29, 30].
Interestingly, FLIPI resulted in being predictive of
progression-free survival (PFS) in FL patients receiving
immunochemotherapy such as rituximab-cyclophospham-
ide-vincristine-prednisone (R-CVP) [31] or rituximab-
cyclophosphamide-doxorubicin-vincristine-prednisone (R-
CHOP) [32].
The recent improvement in survival of FL patients makes
it difficult to employ OS as endpoint for statistical analysis.
In addition, PFS is recommended as the primary end-
point for clinical trials [20]. At the time of the analysis
of FLIPI, most of the patients were never treated with
immunotherapy, such as rituximab or radioimmunotherapy,
and some important clinical and laboratory parameters were
not available (e.g., the size of the largest tumor mass and
serum β2-microglobulin levels). For these reasons, in 2004 an
international consortium coordinated by the International
Follicular Lymphoma Prognostic factor project was estab-
lished and a new prognostic study was launched (FLIPI2
study) using PFS as main endpoint and integrating all the
modern parameters prospectively collected in the univariate
and multivariate analyses. The FLIPI2 thus built relies on 5
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Table 1: Risk categories according to FLIPI index.
Risk group Number of factors Distribution of patients (%) 5-year OS, % (SE) 10-year OS, % (SE) RR 95% CI
Low 0-1 36 90.6 (1.2) 70.7 (2.7) 1.0 NA
Intermediate 2 37 77.6 (1.6) 50.9 (2.7) 2.3 1.9–2.8
High ≥3 27 52.5 (2.3) 35.5 (2.8) 4.3 3.5–5.3
Table 2: Risk categories according to FLIPI2.
Group Number of factors Percentage of patients 3-year PFS (%) 5-year PFS (%) HR (95% CI)
Low 0 20 91 79.5 1.0
Intermediate 1-2 53 69 51 3.19 (2.0–5.15)
High ≥3 27 51 19 5.8 (3.5–9.4)
prognostic parameters: longest diameter of the largest tumor
mass > 6 cm, serum β2-microglobulin level > UNL, bone
marrow involvement, hemoglobin ≤ 12 g/L, and age > 60
years [6] (Table 2).
A subsequent study involved 498 patients consecutively
diagnosed with FL between 1980 and 2008 in a single insti-
tution [33]. 418 had all the parameters needed for FLIPI
calculation and 280 patients had all the parameters needed
for FLIPI2 calculation. To compare the performance of two
predictors in terms of discriminatory power, the Harrell C
statistics were used [34]. Applying Harrell C statistics to each
parameter of 2 prognostic scores, FLIPI2 produced a more
discriminating index compared to FLIPI.
In addition to FLIPI and FLIPI2, several data are now
available suggesting that novel prognostic factors may be
relevant for supporting clinical decision in FL patients;
among these the study of minimal residual disease and the
use of FDG-PET to define the quality of response to systemic
treatment are the most promising ones.
6. Indolent Non-Follicular Lymphoma
The REAL classification in 1994 [35], as well as the sub-
sequent WHO classifications in 2001 [36] and 2008 [37],
besides the more frequent group of FL, comprised other
specific subtypes of low-grade lymphomas, namely small
lymphocytic, marginal zone lymphoma (of MALT, nodal and
splendid type), and lymphoplasmacytic lymphoma.
A subset of patients with indolent non-follicular lym-
phomas are frequently managed with a watch and wait policy,
and treated only at progression. In this regard in 2002 a
study focused on and validated previous prognostic criteria
for watch and wait policy and identified LDH level and
number of extranodal sites having prognostic relevance for
progression-free survival (PFS) [38]. On the other side,
patients with advanced-stage disease are commonly treated
with a systemic therapy, ranging from oral alkylators to mod-
ern immunochemotherapy approaches. Also in this sub-
group a prognostic score able to guide the choice of appro-
priate therapeutic strategy in individual patients is greatly
needed, giving that the few studies aimed to this purpose [2]
were based on patients treated before the introduction of the
novel monoclonal antibodies and purine analogues.
Moreover, several demographic, clinical, and biological
factors demonstrated the same predictive relevance when
evaluated in different lymphoma subtype-specific retrospec-
tive series [39–42].
Some papers have been focused on describing and vali-
dating prognostic factors in single lymphoma subtypes, with
the development of specific-entity scores based on retrospec-
tive series, for instance, splenic marginal zone lymphoma
(SMZL).
In 2006 the Intergruppo Italiano Linfomi (IIL) (now
Fondazione Italiana Linfomi) carried out a study to assess the
outcome of splenic marginal zone lymphoma (SMZL) and to
identify prognostic factors in 309 patients [39]. Values that
maintained a negative influence on lymphoma-specific
survival (LSS) in multivariate analysis were hemoglobin less
than 12 g/dL, LDH level > UNL, and albumin level less than
3.5 g/dL. Using these 3 variables, 3 prognostic categories
emerged: low-risk group (41%) with no adverse factors,
intermediate-risk group (34%) with one adverse factor,
and high-risk group (25%) with 2 or 3 adverse factors. The
5-year CSS rate was 88% for the low-risk group, 73% for the
intermediate-risk group, and 50% for the high-risk group.
Recently, the international SMZL Study Group reported a
retrospective study on 593 SMZL patients. In the training set,
hemoglobin (P = 0.003), platelet count (P = 0.043), LDH
(P = 0.011), and extrahilar lymphadenopathy (P = 0.020)
were the factors independently influencing LSS. Applying
specific cut-points low-, intermediate- and high-risk groups
with significantly different 5-year LSS of 94%, 78%, and
67%, respectively, were identified. In the validation set the
system also separated 3 groups with significantly different
5-year LSS [43].
7. New Projects on Prognostication of
Indolent Lymphomas
So far, a widely accepted prognostic tool for clinical usage
for indolent non-follicular B-cell lymphomas is lacking.
Although comprising a heterogeneous group of single rare
diseases, with specific biologic and clinical features, low-
grade non-follicular lymphomas displayed many common
characteristics as indolent behaviour, treatment management
and long-lasting survival.
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For these reasons, giving the success of FLIPI2 project for
FL, we thought it would be useful to start a new study (NF10
study) based on the prospective registration in a relatively
short period of time of patients with indolent low-grade
non-follicular lymphoma for whom it would be possible
to collect an exhaustive set of clinical data and biological
information. Moreover, prospective collection of data could
eventually allows to collect epidemiological data and build
time-dependent prognostic scores, that is, models where
patients acquiring additional risk factor at a time subsequent
to the diagnosis could shift to the next prognostic level and
their follow-ups are splitted in two separate parts and the
two parts are treated as different subjects. These models
have already been demonstrated to be promising in chronic
diseases, such as myeloproliferative neoplasms [44], and
could reveal interest in assessing the prognosis at any time
during the whole natural history of long-lasting diseases as
indolent non-follicular low-grade lymphomas.
8. Conclusions
In conclusion, although FL is generally defined as an indolent
lymphoma, patients’ outcome is heterogeneous and can be
predicted by several prognostic factors and by specific avail-
able prognostic models. Studies in molecular biology [45]
and PET response [25, 46] identify novel prognostic factors
that will represent the basis for future development of risk-
adapted therapies.
So far, a widely accepted prognostic tool for clinical usage
for indolent non-follicular B-cell lymphomas is largely
awaited. For these reasons, giving the success of FLIPI2
project for FL, the Fondazione Italiana Linfomi launched a
prospective study (NF10 study) for defining a new prognostic
tool for indolent low-grade non-follicular lymphomas.
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